# One-two punch: clear senescent cells after chemotherapy

Source: https://onco.cc/ideas/idea-senolytics-after-chemo/  
OnCo record `idea-senolytics-after-chemo` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chemotherapy leaves behind senescent cells that inflame tissues and help tumours relapse. A short course of senolytic drugs afterwards might reduce relapse and long-term side effects at once.

## Summary

This idea proposes a one-two punch: chemotherapy leaves senescent cells that inflame tissues and help tumours relapse, so a short senolytic course afterwards might cut relapse and late side effects at once. Therapy-induced senescence promotes relapse, cachexia and frailty in models, and senolytics (navitoclax, BCL-XL PROTACs, dasatinib plus quercetin) and uPAR CAR-T clear such cells preclinically (Cellular senescence pathway). The hypothesis is that senolytic consolidation reduces relapse and frailty in patients with a high senescence burden measured by p16, and platelet-sparing BCL-XL degraders remove the toxicity barrier. The test is a randomised phase 2 of such a degrader against placebo after adjuvant chemotherapy in Triple-negative breast cancer (TNBC) or Ovarian cancer.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Tags: mechanism; open-question
- Hypothesis: Senolytic consolidation after chemotherapy reduces relapse and treatment-related frailty in patients with high post-treatment senescence burden (p16 expression in blood cells or tumour).
- Rationale: Lowe, Demaria, and Kirkland preclinical data; p16INK4a in T cells is a validated senescence biomarker; platelet-sparing BCL-XL degraders remove the main toxicity barrier.
- Proposed test: Randomised phase 2 of a platelet-sparing BCL-XL degrader vs placebo after adjuvant chemotherapy in TNBC or ovarian cancer, endpoints DFS and geriatric-assessment frailty scores.
- Maturity: preclinical-evidence

## Sources

- Demaria et al., Cellular senescence promotes adverse effects of chemotherapy and cancer relapse (Cancer Discovery 2017): https://doi.org/10.1158/2159-8290.CD-16-0241

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/)
- technologies: [Geriatric assessment](https://onco.cc/technologies/geriatric-assessment/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/), [Senolytics after cancer treatment](https://onco.cc/technologies/rejuv-frontier-senolytics/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/)
- institutions: [Mayo Clinic](https://onco.cc/institutions/mayo-clinic/), [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- pathways: [Cellular senescence](https://onco.cc/pathways/senescence/), [Intrinsic apoptosis (BCL-2 family)](https://onco.cc/pathways/apoptosis-bcl2/)
- terms: [Hallmark (2022): senescent cells](https://onco.cc/terms/senescent-cells/)
- key papers: [Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse](https://onco.cc/key-papers/paper-demaria-cancer-discov/)

---
JSON: https://onco.cc/api/v1/entities/idea-senolytics-after-chemo.json